Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.20 | N/A | +10.50% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.20 | N/A | +10.50% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding current market conditions. They highlighted their commitment to long-term growth despite recent performance.
Management acknowledged the ongoing challenges in the market.
They emphasized a focus on long-term strategies despite short-term setbacks.
Alnylam Pharmaceuticals reported a wider-than-expected loss per share, which contributed to a decline in stock price by 4.73%. The lack of revenue data and absence of guidance updates left investors uncertain about the company's future performance. Management's cautious tone suggests they are facing challenges but remain focused on long-term strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FORTINET INC
Feb 5, 2018